Business
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a
About this update from Aptorum Group Limited
[{"type":"text","content":" NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--\nRegulatory News:\n\nAptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London.\n\nAt the annual general meeting, the required number of shareholders of the Company:\n\n\nRe-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified;\n\n\nApproved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly known as Marcum Bernstein & Pinchuck LLP) as the Company’s independent auditors for the year ending December 31, 2022 and authorized the Board of Directors to fix the remuneration of the auditors; and\n\n\nApproved that every 10 Class A Ordinary Shares of a par value of US$1.00 per share in the authorized share capital of the Company (including issued and unissued share capital) be consolidated into 1 Class A Ordinary Share of a par value of US$10.00 per share; and that every 10 Class B Ordinary Share of a par value of US $1.00 per share in the authorized share capital of the Company (including issued and unissued share capital) be consolidated into 1 Class B Ordinary Share of a par of US$10.00 per share (the “Share Consolidation” or “Reverse Stock Split”), such that immediately following the Share Consolidation, the authorized share capital of the Company will be US$100,000,000.00 divided into 6,000,000 Class A Ordinary Shares with a nominal or par value of US$10.00 each and 4,000,000 Class B Ordinary Shares with a nominal or par value of US$10.00 each; with such Share Consolidation to be effective on any date on or prior to December 21, 2023 as determined by the Board of Directors (the “Effective Date”); and the Effective Date when determined by the Board of Directors shall be announced by the Company. In the event that no Effective Date has been determined by the Board of Directors, the share capital of the Company shall remain unchanged unless otherwise resolved by the shareholders of the Company; and the authority granted to the Board of Directors in this proposal will termin...